RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the health-care industry, announced that it has entered into a definitive agreement to sell one of its portfolio companies, Bioniche Pharma Holdings Limited to Mylan Inc., a leading, global generic and specialty pharmaceutical company, for $550 million
The office of Sen. Herb Kohl, D-Wis., issued the following news release: Today the U.S. Senate Appropriations Committee voted to pass Senator Herb Kohl's bill intended to reduce the number of pay-for-delay settlements that keep generic drugs off the market. "The cost of brand-name drugs rose nearly ten percent last year.
TRENTON, New Jersey After 20 months running drugmaker Sanofi-Aventis SA, Chris Viehbacher wants to end the roller coaster of revenue peaks and valleys as blockbuster drugs climb to billions in sales and suddenly plummet when generic competition hits.
Teva Pharmaceutical Industries Ltd. today announced that the Competition Bureau in Canada has reached an agreement with Teva Canada Limited and the Merckle Group, carrying on business as ratiopharm, stating that they will not challenge the transaction and the Companies are free to close without competition-related risk. About Teva.
Israeli drug maker Teva Pharmaceutical Industries Ltd. said Friday that Canadian antitrust regulators have cleared the company's acquisition of Ratiopharm, owned by the Merckle family. Teva in March beat out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH in a deal worth some euro3.6 billion, or nearly $5 billion.
Research and Markets has announced the addition of Decision Resources, Inc.'s new report "U.S. Healthcare Reform: Impact on the Pharmaceutical Industry" to their offering. Healthcare reform is coming to the United States and everyone is asking, Whats in it for me?
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of NeoStem, Inc., a pharmaceutical firm engaged in stem cell therapies and generic pharmaceuticals in China.
July 29In the wake of health reform's passage into law, Hospira Inc. will begin testing a cheaper version of a popular anemia biotech treatment in the first phase of a U.S. clinical trial. Lake Forest-based Hospira said it will begin the first phase of trials for a "biosimilar," or a biogeneric, version of brand-name Epogen in patients with renal
The Senate Special Committee on Aging issued the following news release: Today the U.S. Senate Appropriations Committee voted to pass Senator Herb Kohl's bill intended to reduce the number of pay-for-delay settlements that keep generic drugs off the market.
PARIS Sanofi-Aventis SA warned Thursday that its core earnings may fall up to 4 percent this year as a result of the U.S. Food and Drug Administration's approval of a generic version of its Lovenox, an injected drug for preventing life-threatening blood clots.
WASHINGTON In a defeat for the powerful drug lobby, a Senate panel approved legislation to prohibit drug companies from paying generic drug makers to delay bringing less costly products to market. The Senate Appropriations Committee approved the measure, which was inserted into a spending bill that funds the Federal Trade Commission's budget.
Finsbury Worldwide Pharmaceutical Trust PLC Annual Financial Report for the year ended 31 March 2010 A copy of the Company's Annual Financial Report can be found on the Company's website at www.finsburywp.com PERFORMANCE SUMMARY *31 31 31 31 31 31 March % March March March March March 2010 Change 2005 2006 2007 20
BOCA RATON, Fla., July 28 Breckenridge announced today that through its agreement with Tris Pharma, the company will market Methylphenidate Solution, the generic version of Methylin marketed by Shionogi Pharma, Inc., under an Abbreviated New Drug Application.
INDIANAPOLIS Eli Lilly and Co. said Wednesday the U.S. Court of Appeals for the Federal Circuit upheld a lower court's ruling that a patent on Lilly's blockbuster cancer drug Gemzar is invalid. The appeals court upheld a a ruling by the U.S. District Court for the Eastern District of Michigan that specifically said Gemzar's method-of-use patent
A new study, 'Biosimilars: pharmacovigilance and risk management,' is now available. "However, the data from pre-authorization clinical studies normally are insufficient to identify all potential differences. The researchers concluded: "Biologicals should always be commercialized with a brand name or the INN plus the manufacturer's name."
HORSHAM, Pa., July 28 Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane Nasal Aerosol in the treatment of seasonal allergic rhinitis.
MONMOUTH JUNCTION, N.J., July 28 Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name Methylin Oral Solution marketed by Shionogi Pharmaceutica
CAMBRIDGE, Mass. Momenta, which is based in Cambridge, Mass., said Sanofi has filed a lawsuit that asked, among other things, for a temporary restraining order and preliminary injunction directing the Food and Drug Administration to suspend its approval of the generic, known by its chemical name enoxaparin.
FTC Testimony: Stopping "Pay-for-Delay" Drug Settlement Agreements is a Top Competition Priority. New Data Show the Number of Potential Anticompetitive Settlements is on the Rise.
The Federal Trade Commission issued the following news release: In testimony today before the U.S. House of Representatives Committee on the Judiciary, Subcommittee on Courts and Competition Policy, the Federal Trade Commission details its work to promote competition and benefit consumers.
European Sales Grew 10% in Local Currencies Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2010. Second Quarter Highlights: "This was truly a superb quarter, in which Teva achieved record-breaking results, including outstanding organic growth," commented Shlomo Yanai, Teva's President and Chief Execu
Israel-based drug maker Teva expects to complete the acquisition of German generic drugs producer Ratiopharm earlier than expected, Reuters said Tuesday citing Teva's president and CEO Shlomo Yanai. The takeover will probably close in the current quarter, the top manager said. The owners of Ratiopharm agreed to sell the company to Teva for over EUR
LAKE FOREST, Ill., July 26 Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin in patients with renal dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States.
Impax Laboratories, a specialty pharmaceutical company, has received final approval from FDA for its abbreviated new drug application for the generic version of Opana extended release 30mg tablet. In June 2010, the company was granted final approval for the 5mg, 10mg, 20mg, and 40mg tablets.
